Execution on Record Orders — Can Margins Hold?
Welspun Corp reports Q2 FY27 against a backdrop of historic order flow (₹25,750 Cr backlog, $5B+ global visibility) and Q1's record profitability. Street expects on-plan execution; the question is whether scales and capex can sustain 14%+ EBITDA margins as volumes ramp.
What to Expect
~₹5,000 Cr
FY27 guidance ₹20,000 Cr implies ~₹5,000 Cr run-rate per quarter; Q1 outturn supports this
~₹700–750 Cr
14%–15% margin expected; Q1's 15.1% (₹756 Cr) represents peak cycle; Q2 may moderate slightly
~₹250–350 Cr
Depends on tax normalization and finance cost; Q1's ₹1,046 Cr was exceptional (∼20% margin)
₹25,000+ Cr
Expect reiteration of ₹25,750 Cr backlog with FY28–FY29 execution milestones
A strong quarter will show sustained EBITDA margins above 14%, steady order inflow, and intact FY27 guidance (₹20,000 Cr revenue, ₹2,850 Cr EBITDA). Evidence of capex progress on US coated-pipe capacity and early HFIW production ramps would support Street confidence. A weak quarter would signal margin compression below 13%, slower US order execution, or any guidance cut—red flags for a commodity-heavy model under inflationary pressure.
On Track?
Welspun Corp is tracking materially ahead of consensus expectations. Q1 FY27 delivered EBITDA of ₹756 Cr—well above the implied quarterly run-rate (₹712 Cr, or ₹2,850 ÷ 4). The order book acceleration, fueled by three major US pipeline wins totaling ~₹30,000 Cr+ in backlog value, extends visibility into FY28 and FY29. However, the Street's debate has shifted from whether Welspun can execute to whether margins can hold as the order mix becomes heavier on US commodity pipes (lower spreads) relative to DI pipes (specialty). FY27 guidance remains intact, but capex intensity and working-capital demands on $5B+ order flow may compress returns if not managed tightly.
What the Street Says
Since Last Quarter
Oct 23, 2026
Board meeting intimated for Q2 FY27 results approval on Oct 29
Routine
Oct 23, 2026
$1.3B US gas pipeline order (coated line pipes for Permian project)
Major positive
Oct 13, 2026
New wholly-owned subsidiary in Jordan incorporated (Welspun Global Jordan)
Structural expansion
Sep 30, 2026
Welspun Special Coating subsidiary incorporated; WMHL stake acquisition delayed to Mar 2027
Execution delay (minor)
Sep 25, 2026
$412.5M HFIW pipe order (company's largest-ever for that product; US facility)
Major positive
Sep 20, 2026
Associate company (EPIC, Saudi Arabia) wins ₹2,000 Cr Aramco pipe contract
Indirect exposure
Aug 27, 2026
Promoter entity (Welspun Investments) sells 2.27% stake at ₹2,275 block deal
Neutral (promoter stake held at ~49.73%)
Aug 20, 2026
$1.8B pipe order (largest-ever single order; US facility execution FY27–FY28)
Major positive
Jul 31, 2026
Completed 51% additional stake acquisition in Welspun Captive Power Generation Limited
Structural consolidation
Jul 27, 2026
Order book reached ₹25,750 Cr (all-time high) with ₹960 Cr pipe supply deal
Major positive
Headline: The past 90 days have been transformational. Welspun secured three mega orders ($1.8B + $1.3B + $412.5M) on its US platform, catapulting the global order backlog to ~$5.25B and the India domestic backlog to ₹25,750 Cr—both all-time highs. The orders span specialty products (HFIW, coated line pipes, gas infrastructure), expanding margins on the commodity base. Corporate actions were routine: new Jordan and coating subsidiaries signal geographic and product diversification; the WMHL stake acquisition delay to Mar 2027 is minor. Ownership: FII rose 3.38pp to 14.61% in Q1 FY27 (signaling foreign investor interest on order flow visibility), while promoters held firm at ~49.73%.
What to Watch on Result Day
1 · Can EBITDA margin sustain above 14%?
Q1's 15.1% was peak-cycle. Q2's mix of US orders (coated pipes, HFIW) is lower-margin than DI. The Street expects 13.5%–14.5% in Q2; anything below 13% signals pricing pressure or execution drag and could reignite the margin-compression debate.
2 · How much capex is the company committing to US capacity?
Three $1B+ orders require plant capex. The call will clarify FY27–FY28 capex guidance. If capex guidance rises materially (>₹1,500 Cr annually), debt/equity metrics tighten and incremental returns per rupee may disappoint.
3 · Is FY27 guidance (₹20,000 Cr revenue, ₹2,850 Cr EBITDA) still intact, or upgraded?
Q1 momentum and order inflow may prompt a raise, especially on the back of higher order certainty. Reiteration at current levels is neutral; a cut is a red flag; an upgrade would electrify sentiment.
Welspun Corp enters Q2 FY27 with an enviable order backdrop—₹25,750 Cr India domestic backlog plus a $5B+ global pipeline—and a track record of Q1 execution (₹756 Cr EBITDA, +35% YoY). The Street is solidly bullish (85.71% Buy) at ₹2,437 target, but expectations have risen. Margin sustainability on US commodity-heavy orders, capex intensity, and FY27 guidance reiteration/upgrade are the lynchpins. A credible call on all three would vindicate the Street's confidence; any crack could trigger a sharp pullback from ATH ₹2900.
Welspun Corp Q2 FY27: Consol PAT +12% YoY to ₹495 Cr on Margin Gains, Revenue +6%
PAT +11.63% YoY · revenue +6.18% · margins expanding · beat vs street
₹4,643.72 Cr
+6.18% YoY
₹495.09 Cr
+11.63% YoY
10.54%
+0.5pp YoY
₹18.91
Welspun Corp's consolidated PAT rose 11.6% YoY to ₹495.09 Cr (owners' share ₹498.56 Cr) on revenue of ₹4,643.72 Cr, up 6.2% YoY — a print that tracks almost exactly with the company's own board-meeting framing of "PAT +12% YoY on margin gains; revenue up 6%." Against our pre-result preview (Q2 revenue ~₹5,000 Cr, EBITDA ₹700-750 Cr, PAT ₹250-350 Cr), revenue came in roughly 7% light, but EBITDA (~₹802 Cr, 17.28% OPM) and PAT both beat the top of the expected range comfortably — profitability, not topline, is the story this quarter.
Q2 FY-2027 vs prior quarters
Margin expansion was the real driver: operating EBITDA margin rose to 17.28% from 16.05% a year ago, and net margin to 10.66% from 10.14%, helped by a better cost-of-materials ratio (62.7% of revenue vs 63.3% YoY) even as depreciation (+54% YoY, capex-led) and other expenses rose sharply on a widened consolidation base (WCPGL stake increased to 73.9%, Sintex entities, new JVs). Sequentially PAT looks down 52.7% QoQ (₹495.09 Cr vs ₹1,047.88 Cr), but that comparison is misleading: Q1 FY27 PAT included a ₹547.93 Cr one-off gain on the sale of EPIC shares; stripped of that, Q1's adjusted PAT was ~₹499.95 Cr, making Q2 essentially flat QoQ on a like-for-like basis, with OPM easing from Q1's 19.73%.
The stock went into the print at ₹2,529, down 7.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
FY27 revenue target ₹20,000 Cr maintained (not increased). EBITDA target ₹2,850 Cr on track. Capex for KSA and US projects to be completed by FY27 year-end, full impact in FY28. FY29 early-stage discussions ongoing, no orders booked yet.
— This quarter: met
The standalone (parent-only) print tells a weaker story — PAT fell to ₹141.83 Cr from ₹365.75 Cr a year ago, but that prior-year quarter carried a ₹163.49 Cr exceptional gain; even adjusting for it, standalone PBT fell from ₹281.82 Cr to ₹186.00 Cr. This >3% divergence from the consolidated growth story reflects that subsidiary and JV contributions (Sintex, US/KSA pipe units, the EPIC associate) are now driving group profitability more than the parent entity alone. At the segment level, Steel held PBT near flat (₹571.64 Cr vs ₹552.81 Cr YoY) while the Others (plastics, including Sintex) segment's operating loss widened to ₹43.51 Cr from ₹28.29 Cr, a growing drag management will need to address.
W1
Can OPM hold near 17%+ as H2 volumes ramp, given it already eased from Q1's (one-off-inflated) 19.73% to 17.28%?
W2
FY27 guidance (₹20,000 Cr revenue / ₹2,850 Cr EBITDA) implies ~₹11,275 Cr of H2 revenue vs ₹8,725 Cr in H1 — watch Q3/Q4 execution on the record order book and new US/Jordan capacity (US expansion due March 2028, full P&L impact from FY28).
W3
Others/plastics segment loss widened to ₹43.51 Cr this quarter — watch whether Sintex-related units narrow losses or keep dragging consolidated margins.
Clean typed statement, both schedules extracted; consol PBT bridges via PBT-before-JV (613.67) + share of JV/associate profit (41.91), no exceptional-items line used at consol level in any period. Consol Q1 FY27 PAT included a one-off ₹547.93 Cr gain on sale of EPIC shares (Note 4) not present in Q2 FY27 or Q2 FY26, so YoY is clean but QoQ is distorted. Standalone Q2 FY26 included a ₹163.49 Cr exceptional gain (NSPL stake sale), inflating that base. NCI took -₹3.47 Cr of Q2 FY27 consol PAT (owners' share ₹498.56 Cr).